Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China

CompletedOBSERVATIONAL
Enrollment

288

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

July 29, 2021

Study Completion Date

December 24, 2021

Conditions
Pulmonary Embolism
Interventions
DRUG

Rivaroxaban(Xarelto, BAY 59-7939)

The dosage and the anticoagulation duration is decided by investigators. As list in product information, the PE treatment dosage of rivaroxaban is 15mg bid for first 21 days and then 20mg qd. If CrCl is 30-49 ml/min and bleeding risk is over VTE recurrence risk, 20mg qd can be replaced with 15mg qd.

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY